Role of adiponectin in patients with end-stage renal failure

authors:

avatar Sara Beigrezaei , avatar Maryam Heidari , avatar Mohammad Reza Tammaddon ORCID , *

Koomesh: Vol.19, issue 3; 515-522
published online: September 02, 2017
article type: Research Article
received: September 01, 2016
accepted: March 02, 2017

how to cite: Beigrezaei S, Heidari M, Tammaddon M R. Role of adiponectin in patients with end-stage renal failure. koomesh. 2017;19(3):e152897. 

Abstract

Adiponectin is a cytokine produced by the adipose tissue. This collagen-like protein has 244-amino acid and its concentration in plasma of healthy individuals is 5-40 μg / mL. In fact, adiponectin comprises 1% of the total serum protein.  Although, adiponectin has anti-inflammatory and anti-atherogenic effects in physiological conditions and plays a key role in lipid and glucose metabolism and energy balance as well. However, in patients with end-stage renal disease, it is not a protector due to the changes in the structure and function, and also is considered as a risk factor. So with regard to the prevalence of atherosclerosis in patients with end stage renal disease, adiponectin may be a marker for indentifying the cardiovascular involvement of these patients.

References

  • 1.

    Heidari M, Nasri P, Nasri H. Adiponectin and chronic kidney disease; a review on recent findings. J Nephropharmacol 2015; 4: 63-68.

  • 2.

    Junaid Nazar CM, Kindratt TB, Ahmad SM, Ahmed M, Anderson J.Barriers to the successful practice of chronic kidney diseases at the primary health care level; a systematic review. J Renal Inj Prev 2014; 3: 61-67.

  • 3.

    Ardalan MR, Sanadgol H, Nasri H, Baradaran A, Tamadon MR, Rafieian-Kopaei R. Impact of vitamin D on the immune system in kidney disease. J Parathyr Dis 2013; 1: 17-20.

  • 4.

    Nasri H. Aggravating role of inflammation in diabetic kidney disease. J Inj Inflamm 2016; 1: e03.

  • 5.

    Montazeri Taleghani H, Soori R, Rezaeian N, Khosravi N. Changes of plasma leptin and adiponectin levels in response to combined endurance and resistance training in sedentary postmenopausal women. Koomesh 2012; 13: 269-277. (Persian).

  • 6.

    Nogueiras R, Wiedmer P, Perez-Tilve D et al. The central melanocortin system directly controls peripheral lipid metabolism. J Clin Invest 2007; 117: 3475-3488.

  • 7.

    Kafeshani M. Diet and immune system. Immunopathol Persa 2015; 1: e04.

  • 8.

    Antoniades C, Antonopoulos AS, Tousoulis D, Stefanadis C. Adiponectin: from obesity to cardiovascular disease. Obes Rev 2009; 10: 269-279.

  • 9.

    Chandra A, Biersmith M, TolouianR. Obesity and kidney protection. J Nephropathol 2014; 3: 91-97.

  • 10.

    Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endoc Rev 2005; 26: 439-451.

  • 11.

    Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S, et al. Impaired multimerization of human adiponectin mutants associated with diabetes: molecular structure and multimer formation of adiponectin. J Biol Chem 2003; 278: 40352-40363.

  • 12.

    Rothenbacher D, Brenner H, Marz W, Koenig W: Adiponectin, risk of coronary heart disease and correlations with cardiovascular risk markers. Eur Heart J 2005; 26: 1640-1646.

  • 13.

    Tripepi G, Mattace Raso F, Sijbrands E, Seck MS, Maas R, Boger R, et al. Inflammation and asymmetric dimethylarginine for predicting death and cardiovascular events in ESRD patients. Clin J Am Soc Nephrol 2011; 6: 1714-1721.

  • 14.

    Malyszko J, Malyszko JS, Brzosko S, Wolczynski S, Mysliwiec M. Adiponectin is related to CD146, a novel marker of endothelial cell activation/injury in chronic renal failure and peritoneally dialyzed patients. J Clin Endocrinol Metab 2004; 89: 4620-4627.

  • 15.

    Bajaj M, Suraamornkul S, Romanelli A, Cline GW, Mandarino LJ, Shulman GI, DeFronzo RA. Effect of a sustained reduction in plasma free fatty acid concentration on intramuscular long-chain fatty Acyl-CoAs and insulin action in type 2 diabetic patients. Diabetes 2005; 54: 3148-3153.

  • 16.

    Momeni A. Cardiovascular complications of renal failure in hemodialysis patients. Ann Res Dial 2016; 1: e05.

  • 17.

    Ezeonwu BU, Nwafor I, Nnodim I, Ayodeji A, Ajaegbu O, Maduemem E, Okolo AA. Risk factors for chronic kidney diseasein children attending pediatric outpatient clinic in federal medical center Asaba. J Prev Epidemiol 2016; 1: e10.

  • 18.

    Oh DK, Ciaraldi T, Henry RR. Adiponectin in health and disease. Diabetes Obes Metab 2007; 9: 282-289.

  • 19.

    Hajian S. Positive effect of antioxidants on immune system. Immunopathol Persa 2015; 1: e02.

  • 20.

    Tavafi M. Antioxidants against contrast media induced nephrotoxicity. J Renal Inj Prev 2014; 3: 55-56.

  • 21.

    Baradaran A. Concepts towards endothelial dysfunction in diabetes mellitus. Angiol Persica Acta 2016; 1: e02.

  • 22.

    Rasregari F. The healthy diet for cardiovascular disease. Acta Persica Pathophysiol 2016; 1: e02.

  • 23.

    Hosseini SA, Abdollahi AA, Behnampour N, Salehi A. The relationship between coronary risk factors and coronary artery involvement based on angiogrpahy findings. Koomesh 2012; 14: 7-12. (Persian).

  • 24.

    Awano T, Saito T, Yasu T, Saito T, Nakamura T, Namai K, et al. Close association of hypoadiponectinemia with arteriosclerosis obliterans and ischemic heart disease. Metabolism 2005; 54: 653-656.

  • 25.

    Iglseder B, Mackevics V, Stadlmayer A, Tasch G, Ladurner G, Paulweber B. Plasma adiponectin levels and sonographic phenotypes of subclinical carotid artery atherosclerosis: data from the SAPHIR Study. Stroke 2005; 36: 2577-2582.

  • 26.

    Langenberg C, Bergstrom J, Scheidt-Nave C, Pfeilschifter J, Barrett-Connor E. Cardiovascular death and the metabolic syndrome: role of adiposity-signaling hormones and inflammatory markers. Diabetes Care 2006; 29: 1363-1369.

  • 27.

    Kanaya AM, Wassel Fyr C, Vittinghoff E, Havel PJ, Cesari M, Nicklas B, et al. Serum adiponectin and coronary heart disease risk in older Black and White Americans. J Clin Endocrinol Metab 2006; 91: 5044-5050.

  • 28.

    Dieplinger B, Poelz W, Haltmayer M, Mueller T. Hypoadiponectinemia is associated with symptomatic atherosclerotic peripheral arterial disease. Clin Chem Lab Med 2006; 44: 830-833.

  • 29.

    Kojima S, Funahashi T, Otsuka F, Maruyoshi H, Yamashita T, Kajiwara I, et al. Future adverse cardiac events can be predicted by persistently low plasma adiponectin concentrations in men and marked reductions of adiponectin in women after acute myocardial infarction. Atherosclerosis 2007; 194: 204-213.

  • 30.

    Cavusoglu E, Ruwende C, Chopra V, Yanamadala S, Eng C, Clark LT, et al. Adiponectin is an independent predictor of all-cause mortality, cardiac mortality, and myocardial infarction in patients presenting with chest pain. Eur Heart J 2006; 27: 2300-2309.

  • 31.

    Roubicek T, Bartlova M, Krajickova J, Haluzikova D, Mraz M, Lacinova Z, et al. Increased production of proinflammatory cytokines in adipose tissue of patients with end-stage renal disease. Nutrition 2009; 25: 762-768.

  • 32.

    Tamadon MR, Baradaran A, Rafieian-Kopaei M. Antioxidant and kidney protection; differential impacts of single and whole natural antioxidants. J Renal Inj Prev 2013; 3: 41-42.

  • 33.

    Badwal S, Kumar A, Singh S, Dutta V. Immunostaining of podocyte associate markers in renal biopsies; a valuable adjunct in characterisation of podocytopathies. Immunopathol Persa 2016; 2: e19.

  • 34.

    Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115: 911-919.

  • 35.

    Rafieian-Kopaei M, Nasri H. Correlation of serum leptin with levels of hemoglobin in hemodialysis. J Nephropharmacol 2012; 1: 23-26.

  • 36.

    Nasri H. World lupus day 2016. Immunopathol Persa 2015; 1: e06.

  • 37.

    Kato A, Odamaki M, Ishida J, Hishida A, Association of high-molecular-weight to total adiponectin ratio with pulse wave velocity in hemodialysis patients, Nephron Clin. Pract 2008; 109: 18-24.

  • 38.

    Asadi-Samani M, Bahmani M. Trends on the treatment of atherosclerosis; new improvements. Angiol Persica Acta 2016; 1: e01.

  • 39.

    Nasri H. Impact of diabetes mellitus on parathyroid hormone in hemodialysis patients. J Parathyr Dis 2013; 1: 9-11.

  • 40.

    Amiri M, Hosseini SM. Diabetes mellitus type 1; is it a global challenge? Acta Epidem 2016; 1: e02.

  • 41.

    Shimabukuro M, Higa N, Asahi T, Oshiro Y, Takasu N, Tagawa T, et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab 2003; 88: 3236-3240.

  • 42.

    Liu JJ, Tavintharan S, Lim SC. Comment on: Singer et al. Adiponectin and all-cause mortality in elderly people with Type 2 diabetes. Diabetes Care 2012; 35: 1858-1863.

  • 43.

    Mirhoseini M, Baradaran A, Rafieian-Kopaei M. Medicinal plants, diabetes mellitus and urgent needs. J Herb Med Pharmacol 2013; 2: 53-54.

  • 44.

    Rafieian-Kopaei M, Baradaran A. On the occasion of world diabetes day 2105; act today to change tomorrow. J Renal Endocrinol 2015; 1: e02.

  • 45.

    Martinez Cantarin MP, Waldman SA, Doria C, Frank AM, Maley WR, Ramirez CB, et al. The adipose tissue production of adiponectin is increased in end-stage renal disease. Kidney Int 2013; 83: 487-494.

  • 46.

    Tavafi M, Hasanvand A, Ashoory H. Proximal convoluted tubule cells in ischemia and post-injury regeneration. Acta Pers Pathophys 2016; 1: e05.

  • 47.

    Amiri M, Hosseini SM. Diabetes mellitus type 1; is it a global challenge? Acta Epidem 2016; 1: e02.

  • 48.

    Nasri H. The role of biomarkers in diagnosis of acute kidney injury. Toxicol Persa 2016; 1: e03.

  • 49.

    Ruth Dubin, Mary Cushman, Aaron R Folsom, Linda F Fried, Walter Palmas, Carmen A Peralta, et al. Kidney function and multiple hemostatic markers: cross sectional associations in the multi-ethnic study of atherosclerosis. BMC Nephrol 2013; 12: 3-8.

  • 50.

    Nasri H. Antioxidant therapy for hemodialysis patients. Ann Res Antioxid 2016; 1: e01.

  • 51.

    Jorsal A, Tarnow L, Frystyk J, Lajer M, Flyvbjerg A, Parving HH, et al. Serum adiponectin predicts allcause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy. Kidney Int 2008; 74: 649-654.

  • 52.

    Aghadavod E, Nasri H. What are the molecular mechanisms of oxidant and antioxidant compounds? Ann Res Antioxid 2016; 1: e10.

  • 53.

    Heydari M, Mardani S, Nasri H. The Association of Serum Adiponectin Level and Various Biochemical and Metabolic Factors in Patients under Hemodialysis. J Isfahan Med Sch 2014; 32: 559-609.

  • 54.

    Yilmaz MI, Saglam M, Carrero JJ, Qureshi AR, Caglar K, Eyileten T, et al. Serum visfatin concentration and endothelial dysfunction in chronic kidney disease. Nephrol Dial Transplant 2008; 23: 959-965.

  • 55.

    Nasri P. Mitochondria as a biomarker for cancer therapy. Front Biomark 2016; 1: e01.

  • 56.

    Said S, Hernandez GT. The link between chronic kidney disease and cardiovascular disease. J Nephropathol 2014; 3: 99-104.

  • 57.

    Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 2002; 13: 134-141.

  • 58.

    Nasri P. Predisposing factors of kidney cancers. Front Cancers 2016; 1: e01.

  • 59.

    Nasri H, Rafieian-Kopaei M. Association of serum vitamin D level with age in individuals with normal renal function. J Nephropharmacol 2012; 1: 7-9.

  • 60.

    Lala MA, Nazar CMJ, Lala HA, Singh JK. Interrelation between blood pressure and diabetes. J Renal Endocrinol 2015; 1: e05.

  • 61.

    Nasri H. Ischemic nephropathy; new concepts on its pathophysiology. Angiol Persica Acta 2016; 1: e03.

  • 62.

    Drechsler C, Krane V, Winkler K, Dekker FW, Wanner C. Changes in adiponectin and the risk of sudden death, stroke, myocardial infarction, and mortality in hemodialysis patients. Kidney Int 2009; 76: 567-575.

  • 63.

    Shahnazari B, Forootan M, Tamadon MR, Doustmohamadian S. Secondary hyperparathyroidism in chronic kidney failure. Front Biomed 2016; 1: e01.

  • 64.

    Nasri H. Elevated serum parathyroid hormone is a heart risk factor in hemodialysis patients. J Parathyr Dis 2013; 1: 13-14.

  • 65.

    Nasri H. Trends toward amelioration of renal inflammation and fibrosis in various kidney diseases. J Inj Inflamm 2016; 1: e02.

  • 66.

    Heidari M, Nasri P, Nasri H. Adiponectin and chronic kidney disease; a review on recent findings. J Nephropharmacol 2015; 4: 57-62.

  • 67.

    Ghaderian SB, Beladi-Mousavi SS.The role of diabetes mellitus and hypertension in chronic kidney disease. J Renal Inj Prev 2014; 3: 109-110.

  • 68.

    Nouri P, Nasri H. Irisin and kidney disease; new concepts. J Renal Endocrinol 2015; 1: e03.

  • 69.

    Ajabshir S, Asif A, Nayer A. The effects of vitamin D on the renin-angiotensin system. J Nephropathol 2014; 3: 41-43.

  • 70.

    Nobahar M, Tamadon MR. Barriers to and facilitators of care for hemodialysis patients; a qualitative study. J Renal Inj Prev 2016; 5: 39-44.

  • 71.

    Kacso I, Lenghel A, Bondor CI, Moldovan D, Rusu C, Nita C, et al. Low plasma adiponectin levels predict increased urinary albumin/creatinine ratio intype 2 diabetes patients. Int Urol Nephrol 2012; 44: 1151-1157.

  • 72.

    Kacso IM, Bondor CI, Kacso G. Plasma adiponectin is related to the progression of kidney disease in type 2 diabetespatients. Scand J Clin Lab Invest 2012; 72: 333-339.

  • 73.

    Saraheimo M, Forsblom C, Fagerudd J, Teppo AM, Pettersson-Fernholm K, Frystyk J, et al. Serum adiponectin is increased in type 1 diabetic patients with nephropathy. Diabetes Care 2005; 28: 1410-1414.

  • 74.

    Saraheimo M, Forsblom C, Thorn L, Wadn J, Rosengrd-Brlund M, Heikkil O, et al. Serum adiponectin and progression of diabetic nephropathy in patients withtype 1 diabetes. Diabetes Care 2008; 31: 1165-1169##.